Business
Preliminary Data in Faridoxorubicin Phase 1b Trial
Avacta Group plc will announce preliminary clinical data for its Faridoxorubicin Phase 1b trial in salivary gland cancer on December 17, 2025, with a presentation available via the Investor Meet Platform at 10:00 AM GMT. This announcement pertains to the company's development of next-generation peptide drug conjugates (PDCs) designed to target anti-tumor payloads directly to tumors, aiming to reduce toxicity and improve efficacy. Disclaimer*
About this update from Avacta Group Plc
[{"type":"text","content":"\n\n \n \nAvacta Group plc\n(\"Avacta\", the \"Group\" or the \"Company\")\n \nAvacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort\n \n \nLONDON and PHILADELPHIA - December 8, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, expects to announce initial Faridoxorubicin Phase 1b data in the salivary gland cancer indication on December 17, 2025. A presentation will be made available via the Investor Meet Platform on December 17, 2025, at 10:00 AM GMT. The link to view the presentation is below. Investors can register for the webinar and submit questions through the platform link below at any time before the presentation.\n \nhttps://www.investormeetcompany.com/avacta-group-plc/register\n \n-Ends-\n \nFor further information from Avacta, please contact:\n \n\n\n\n\nAvacta Group plc\nChristina Coughlin, Chief Executive Officer\n\n\nhttps://avacta.com/\nvia ICR Healthcare\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nPeel Hunt (Nomad and Joint Broker)\nJames Steel / Chris Golden\n \n\n\nwww.peelhunt.com\n \n\n\n\n\n \nZeus (Joint Broker)\nJames Hornigold / George Duxberry\nDominic King\n \n\n\n \n \nwww.zeuscapital.co.uk\n \n\n\n\n\nICR Healthcare (Europe/UK media and investors)\nMary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert\n\n\[email protected]\n \n\n\n\n\n \nInvestor Contact\nRenee Leck\nTHRUST Strategic Communications\n \n\n\n \[email protected]\n \n\n\n\n\nMedia Contact\nCarly Scaduto\nTHRUST Strategic Communications\n \n\n\[email protected] \n\n\n\n\n \n \nAbout Avacta - www.avacta.com\nAvacta is a clinical stage life sciences company developing an innovative proprietary drug delivery peptide drug conjugate (PDC) platform, pre|CISION®. The pre|CISION® platform uniquely enables the repurposing of a range of oncology drugs as PDC payloads with the goal to significantly reduce toxicity and side effects for patients by concentrating the drug directly in the tumor.\n \nAbout pre|CISION®\nThe key aspect of pre|CISION® is its peptide drug conjugates (PDC) technology. The combination...